General | 03 November 2026
Balaji Amines Q2 FY27 consolidated PAT surged by 81% to Rs. 67 Cr
The next product planned for commercialization is N-Methyl Morpholine
The next product planned for commercialization is N-Methyl Morpholine
Board approves Rs. 70 crore CapEx plan
Consolidated revenue from operations jump 104.9% year-on-year to Rs.934.37 crore
Revenue from operations grew by 13.3% YoY to reach Rs. 826 crore
Net income for the quarter stood at $30 million
H1 FY27 PAT witnessed a massive 155.7% YoY explosion, hitting Rs. 113.77 crore as against Rs. 44.45 crore
However, statutory Profit After Tax (PATMI) fell 24% YoY to Rs. 421 crore due to an 18% spike in net finance costs
Color business leads growth as operating income surges 25.5%; company raises its full-year earnings outlook
Adjusted EBITDA also declined to $191.4 million from $222.4 million in the third quarter of 2025
Agrichemical major reports 22% fall in adjusted EBITDA; CEO Gaël Hili steps down
Raises 2026 price hikes to $500 million amid Middle East conflict
Unveils Rs. 500 crore capex plan
For the first time, the Oil and Gas segment has overtaken Pharmaceuticals as Aether's largest revenue contributor
Gulf has pledged to empower 125,000 women in mobility
EBITDA margin also improved by 70 basis points to 15.6%, against 15% in Q2 FY26
FMC attributed much of the deterioration to commercial actions announced on October 15, which accounted for approximately $639 million in lost revenue and $672 million in negative Adjusted EBITDA impact
Lifts IET order outlook above $50 billion as AI and LNG demand surge
The bioenergy division continued to drive execution, expanding its revenue by 8.3% year-on-year
Achieves record quarterly revenue and EBITDA driven by sustained business growth
International business grew 29.5%, with strong performance across all regions
Subscribe to our newsletter & stay updated.
